fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Framycetin sulfate

Form:

2 of 2 products shown

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.

Soframycin · DIN 02224895 · 0.5% · Oph Oint-5g Pk

General benefitDormant since February 10, 2023 · checked October 5, 2026 · What does dormant mean?
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
Soframycin · DIN 02224895 Manufacturer: Searchlight Pharma Inc.; listing date 2005-09-27 Health Canada: Dormant since 2023-02-10 · brand SOFRAMYCIN STERILE EYE OINTMENT · ATC S01AA07 FRAMYCETIN · form Ointment · route Ophthalmic · ingredients FRAMYCETIN SULFATE 5 MG/G · company Searchlight pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Soframycin: Formulary list price $19.61 per unit (the source does not state the unit; exact figure $19.6100). What the ministry pays, not the patient.

Ministry pays: $19.6100 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02224895)

Source record
DIN 02224895: Soframycin Raw flags: sec3=Y Item: 520404011; group id 576; item number 1530; lccId None; manufacturer id SLP Source form: Oph Oint-5g Pk; strength: 0.5% Recorded listing: General benefit Source prices (unrounded): $19.6100; ministry $19.6100 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02224895 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=37387
Shortage status: active shortage (reported June 11, 2013, last updated March 14, 2018) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02224895
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since February 10, 2023 — choose a marketed DIN from the same-category list.

Soframycin · DIN 02224887 · 0.5% · Oph Sol

General benefitDormant since February 10, 2023 · checked October 5, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
Soframycin · DIN 02224887 Manufacturer: Searchlight Pharma Inc.; listing date 2005-09-27 Health Canada: Dormant since 2023-02-10 · brand SOFRAMYCIN EYE DROPS · ATC S01AA07 FRAMYCETIN · form Drops · route Ophthalmic · ingredients FRAMYCETIN SULFATE 5 MG/ML · company Searchlight pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Soframycin: Formulary list price $1.37 per unit (the source does not state the unit; exact figure $1.3663). What the ministry pays, not the patient.

Ministry pays: $1.3663 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02224887)

Source record
DIN 02224887: Soframycin Raw flags: sec3=Y Item: 520404010; group id 576; item number 1531; lccId None; manufacturer id SLP Source form: Oph Sol; strength: 0.5% Recorded listing: General benefit Source prices (unrounded): $1.3663; ministry $1.3663 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02224887 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=37386
Shortage status: active shortage (reported June 11, 2013, last updated March 14, 2018) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02224887
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since February 10, 2023 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (S01A, S01AA): coverage varies; not interchangeable

  • Gentamicin (Garamycin): general benefit
  • Bacitracin zinc + polymyxin b (Polysporin): general benefit
  • Tobramycin (Tobrex): general benefit
  • Gatifloxacin (Zymar (with preservative)): not a benefit
  • Moxifloxacin (Vigamox): not a benefit

Framycetin sulfate & gramicidin & dexamethasone

All products: general benefit

Sofracort · DIN 02224623 · 5 mg & 50 mcg & 0.5 mg/mL · Oph/Ot Sol

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
No interchangeable product listed in the Ontario extract
Sofracort · DIN 02224623 Manufacturer: Sanofi Aventis Pharma; listing date 2001-10-11 Health Canada: Marketed since 2024-07-30 · brand SOFRACORT · ATC S03CA01 DEXAMETHASONE AND ANTIINFECTIVES, S03CA01 DEXAMETHASONE AND ANTIINFECTIVES · form Drops · route Ophthalmic, Otic · ingredients FRAMYCETIN SULFATE 5 MG/ML, DEXAMETHASONE (DEXAMETHASONE SODIUM METASULPHOBENZOATE) 0.5 MG/ML, GRAMICIDIN 0.05 MG/ML · company Cheplapharm arzneimittel gmbh · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Sofracort: Formulary list price $2.22 per unit (the source does not state the unit; exact figure $2.2212). What the ministry pays, not the patient.

Ministry pays: $2.2212 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02224623)

Source record
DIN 02224623: Sofracort Raw flags: sec3=Y Item: 520404012; group id 577; item number 1532; lccId None; manufacturer id SAV Source form: Oph/Ot Sol; strength: 5mg & 50mcg & 0.5mg/mL Recorded listing: General benefit Source prices (unrounded): $2.2212; ministry $2.2212 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02224623 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=37363 Therapeutic Notes (formulary) The risk of ototoxicity with topical aminoglycoside may increase with prolonged therapy. Topical use of antibiotics increases the likelihood of development of bacterial resistance, especially with prolonged use, sometimes rendering the systemic use of this antibiotic class useless in these patients.
Shortage status: resolved shortage (ended October 7, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02224623
Shortage record checked October 6, 2026

Other products in the same Health Canada class (S01A, S01AA): coverage varies; not interchangeable

  • Gentamicin (Garamycin): general benefit
  • Bacitracin zinc + polymyxin b (Polysporin): general benefit
  • Tobramycin (Tobrex): general benefit
  • Gatifloxacin (Zymar (with preservative)): not a benefit
  • Moxifloxacin (Vigamox): not a benefit
Other drugs in the same formulary class (52:04:04 Antibiotics) and how they are covered

Matched class: 52:04:04 Antibiotics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: GENTAMICIN & BETAMETHASONE SODIUM PHOSPHATE, GENTAMICIN SULFATE, POLYMYXIN B SULFATE & BACITRACIN (ZINC), POLYMYXIN B SULFATE & GRAMICIDIN, TOBRAMYCIN, TOBRAMYCIN & DEXAMETHASONE 52:04:04 Antibiotics

GENTAMICIN SULFATE

· 1 products · General benefit · strengths: 0.3% · Oph Oint-3.5g Pk

POLYMYXIN B SULFATE & BACITRACIN (ZINC)

· 1 products · General benefit · strengths: 10000U & 500U/g · Oph Oint 3.5g Pk

TOBRAMYCIN

· 3 products · General benefit · strengths: 0.3% · Oph Oint, Oph Sol

GATIFLOXACIN

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 0.3% w/v · Oph Sol

MOXIFLOXACIN HYDROCHLORIDE

· 8 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 0.5% · Oph Sol-3mL Pk (Preservative-Free)

GENTAMICIN & BETAMETHASONE SODIUM PHOSPHATE

· 1 products · General benefit · strengths: 3mg & 1mg/mL · Oph/Ot Drops

POLYMYXIN B SULFATE & GRAMICIDIN

· 1 products · General benefit · strengths: 10000U & 0.025mg/mL · Oph/Ot Sol

TOBRAMYCIN & DEXAMETHASONE

· 2 products · General benefit · strengths: 0.3% & 0.1% · Oph Oint, Oph Susp

CIPROFLOXACIN AND DEXAMETHASONE

· 3 products · Limited Use, codes 509 · strengths: 0.3% w/v & 0.1% w/v · Otic Susp-7.5mL Pk (With Preservative) Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 52:04:04
Full class listing Related classes: 52:04:12 Other Anti-Infectives, 52:08:92 Anti-Inflammatory Agents, Miscellaneous Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
Product monograph unavailable: no marketed product found
What the Health Canada label says it is for
1 INDICATIONS SOFRACORT (framycetin sulfate, dexamethasone and gramicidin ophthalmic/otic solution) is indicated for: • Eye: Blepharitis and infected eczema of the eyelid; allergic, infective and rosacea conjunctivitis; rosacea keratitis; scleritis and episcleritis; iridocyclitis, and other inflammatory conditions of the anterior segment of the eye. • Ear: Otitis externa (acute and chronic) and other inflammatory and seborrheic conditions of the external ear. SOFRACORT contains antibacterial ingredients, framycetin and gramicidin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of framycetin and gramicidin, SOFRACORT should only be used for the authorized indication. 1.1 Pediatrics Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use (see 7.1.3 Pediatrics). 1.2 Geriatrics Geriatrics: No data are available to Health Canada; therefore, Health Canada has not authorized an indication for geriatric use. https://pdf.hres.ca/dpd_pm/00076258.PDF PM date: not printed or not captured Source product: SOFRACORT; DIN 02224623; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Soframycin · DIN 02224895 Shortage status: active shortage (reported 2013-06-11, last updated 2018-03-14) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02224895

Check this DIN again

Soframycin · DIN 02224887 Shortage status: active shortage (reported 2013-06-11, last updated 2018-03-14) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02224887

Check this DIN again
Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, September 10, 2026 ↗)